Carrimycin ameliorates lipopolysaccharide and cecal ligation and puncture-induced sepsis in mice
{{output}}
Carrimycin (CA), sanctioned by China's National Medical Products Administration (NMPA) in 2019 for treating acute bronchitis and sinusitis, has recently been observed to exhibit multifaceted biological activities, encompassing anti-inflammatory, antiviral, and... ...
